1. 534TiPA randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for NSCLC with IPF (J-SONIC). (24th November 2019) Authors: Otsubo, K; Kishimoto, J; Kenmotsu, H; Minegishi, Y; Horinouchi, H; Kato, T; Ichihara, E; Shiraki, A; Atagi, S; Ando, M; Yamamoto, N; Okamoto, I Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Empagliflozin improves prognosis and energetic properties through modulating mitochondrial function in failing murine hearts. (14th October 2021) Authors: Shiraki, A; Oyama, J; Shimizu, T; Nakajima, T; Yokota, T; Node, K Journal: European heart journal Issue: Volume 42(2021)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. The DPP4 inhibitor linagliptin exacerbated heart failure due to energy deficiency via downregulation of glucose absorption and utilization in mice. (3rd October 2022) Authors: Shiraki, A; Oyama, J; Shimizu, T; Node, N Journal: European heart journal Issue: Volume 43(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗